Tag Archives: bladder cancer

Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer

March 31, 2024 by Modulight Content
No comments
Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) that targets Nectin-4, has shown promising results in the treatment of bladder cancer. The study investigated use of Nectin-4 targeting photoimmunotherapy in preclinical bladder cancer models. ML7710 was used as light source for activating the therapy in vitro and in vivo.   Read the article here

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light Continue reading →

Optimization of light delivery for non-muscle invasive bladder cancer PDT

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light sources and Continue reading →

Fluorescence imaging & endoscopy for tumor visualization and diagnostics

July 6, 2022 by Modulight Content
No comments
Several fluorescent agents have been approved for fluorescence based diagnosis & intraoperative imaging: Dye generic name Countries Excitation Detection Indications Indocyanine Green (ICG) Worldwide 800 nm Near-infrared (820 nm) Multiple uses: lymphatic mapping, tissue perfusion, visualization of biliary ducts and blood veins, retinal angiography Fluorescein Worldwide 490 nm Green fluorescence (525 nm) Fluorescein angiography or angioscopy (ophthalmology) Methylene Blue Worldwide 665 nm 688 nm Endoscopic polypectomy, chromoendoscopy, lymphatic drainage 5-ALA Hydrochloride (converted to Pp-IX) Worldwide 400 – 410 nm Red fluorescence (620 – 710 nm) Continue reading →Introduction to fluorescence imaging Fluorescence is a phenomenon where substance that has absorbed certain wavelength of light emits it back at another wavelength. These substances are called fluorophores or fluorescent dyes. The emitted light has a longer wavelength than the absorbed one since some energy of the photon is lost in the process. The difference in wavelengths between absorbed and emitted light, called Stokes shift, allows very low background for fluorescence detection by separating it from the excitation light. The process of fluorescence generation is Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2022

March 2, 2022 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – February 2022 Photocure’s blue light cystoscopy is a routine procedure in the management of bladder cancer as it results in better tumor visualization and removal. However, this study found that the positive effects of blue light cystoscopy could extend beyond visualization and result in the induction of systemic antitumor immunity, which can be further boosted with immune checkpoint inhibitors. Modulight nominated this study because bladder cancer is highly recurring and progressive disease with more than 200,000 deaths worldwide annually. Thus, Continue reading →

Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer

February 25, 2022 by Modulight
No comments
Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya    Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya   Blue light cystoscopy/Photodynamic diagnosis (PDD) was shown in rat models of bladder cancer to not only help in visualization and better removal of tumors, but also lead to anti-tumor effects and stimulation of immune system. ML6500 was used as blue light source for PDD.   Read the article here